KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables - Other
Ratios

TherapeuticsMD (TXMD) Amortization - Deferred Charges (2020 - 2022)

TherapeuticsMD (TXMD) has disclosed Amortization - Deferred Charges for 3 consecutive years, with $3.1 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Amortization - Deferred Charges rose 108.67% year-over-year to $3.1 million, compared with a TTM value of $21.6 million through Sep 2022, up 327.83%, and an annual FY2021 reading of $5.7 million, up 124.68% over the prior year.
  • Amortization - Deferred Charges was $3.1 million for Q3 2022 at TherapeuticsMD, down from $7.9 million in the prior quarter.
  • Across five years, Amortization - Deferred Charges topped out at $9.0 million in Q1 2022 and bottomed at $887000.0 in Q4 2020.
  • Average Amortization - Deferred Charges over 3 years is $3.1 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Amortization - Deferred Charges surged 54.98% in 2021, then skyrocketed 611.32% in 2022.
  • Year by year, Amortization - Deferred Charges stood at $887000.0 in 2020, then soared by 72.6% to $1.5 million in 2021, then surged by 101.31% to $3.1 million in 2022.
  • Business Quant data shows Amortization - Deferred Charges for TXMD at $3.1 million in Q3 2022, $7.9 million in Q2 2022, and $9.0 million in Q1 2022.